MX2020011367A - Compuesto oxo-sustituido. - Google Patents
Compuesto oxo-sustituido.Info
- Publication number
- MX2020011367A MX2020011367A MX2020011367A MX2020011367A MX2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- oxo
- inhibitory effect
- substituted compound
- lactamase inhibitory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un compuesto novedoso que tiene un excelente efecto inhibidor de ß- lactamasa; más específicamente, se proporciona un compuesto representado por la fórmula (1a), (1b) u (11) que tiene un excelente efecto inhibidor de ß-lactamasa o una sal farmacéuticamente aceptable del mismo; al usar este compuesto en combinación con un fármaco de ß-lacta o solo, se proporciona un agente preventivo o terapéutico útil para infecciones bacterianas; también se proporcionan agentes preventivos o terapéuticos útiles para tratar diversas enfermedades con el uso combinado del compuesto mencionado anteriormente y fármacos ß-lactámicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018087761 | 2018-04-27 | ||
PCT/JP2019/018011 WO2019208797A1 (ja) | 2018-04-27 | 2019-04-26 | オキソ置換化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011367A true MX2020011367A (es) | 2021-02-09 |
Family
ID=68295570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011367A MX2020011367A (es) | 2018-04-27 | 2019-04-26 | Compuesto oxo-sustituido. |
Country Status (14)
Country | Link |
---|---|
US (3) | US11702431B2 (es) |
EP (1) | EP3786168A4 (es) |
JP (2) | JP7360132B2 (es) |
KR (1) | KR20210005910A (es) |
CN (1) | CN112135830A (es) |
AU (1) | AU2019259818B2 (es) |
BR (1) | BR112020021631A8 (es) |
CA (1) | CA3098433A1 (es) |
EA (1) | EA202092579A1 (es) |
MX (1) | MX2020011367A (es) |
PH (1) | PH12020551772A1 (es) |
SG (1) | SG11202010661SA (es) |
TW (1) | TWI829686B (es) |
WO (1) | WO2019208797A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202038941A (zh) * | 2018-12-28 | 2020-11-01 | 日商大日本住友製藥股份有限公司 | 烷基取代化合物 |
EP4049680A4 (en) * | 2019-10-25 | 2024-01-10 | Sumitomo Pharma Co Ltd | NEW SUBSTITUTED CONDENSED RING CONNECTION |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9422314B2 (en) * | 2012-12-07 | 2016-08-23 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9132140B2 (en) | 2013-01-04 | 2015-09-15 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN104994844A (zh) | 2013-01-04 | 2015-10-21 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
ES2730013T3 (es) * | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CA2947041A1 (en) * | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
RU2686740C2 (ru) | 2014-06-11 | 2019-04-30 | Венаторкс Фармасьютикалс, Инк. | Ингибиторы бета-лактамазы |
CA2952968A1 (en) | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10399996B2 (en) * | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
-
2019
- 2019-04-26 BR BR112020021631A patent/BR112020021631A8/pt active Search and Examination
- 2019-04-26 JP JP2020515615A patent/JP7360132B2/ja active Active
- 2019-04-26 US US17/050,747 patent/US11702431B2/en active Active
- 2019-04-26 SG SG11202010661SA patent/SG11202010661SA/en unknown
- 2019-04-26 EA EA202092579A patent/EA202092579A1/ru unknown
- 2019-04-26 WO PCT/JP2019/018011 patent/WO2019208797A1/ja active Application Filing
- 2019-04-26 TW TW108114791A patent/TWI829686B/zh active
- 2019-04-26 KR KR1020207033733A patent/KR20210005910A/ko active IP Right Grant
- 2019-04-26 CN CN201980028757.2A patent/CN112135830A/zh active Pending
- 2019-04-26 MX MX2020011367A patent/MX2020011367A/es unknown
- 2019-04-26 CA CA3098433A patent/CA3098433A1/en active Pending
- 2019-04-26 AU AU2019259818A patent/AU2019259818B2/en active Active
- 2019-04-26 EP EP19793135.5A patent/EP3786168A4/en active Pending
-
2020
- 2020-10-26 PH PH12020551772A patent/PH12020551772A1/en unknown
- 2020-12-29 US US17/136,806 patent/US11066425B1/en active Active
-
2023
- 2023-04-28 US US18/309,641 patent/US20230287009A1/en active Pending
- 2023-09-21 JP JP2023156567A patent/JP2023168413A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023168413A (ja) | 2023-11-24 |
TW201945006A (zh) | 2019-12-01 |
CN112135830A (zh) | 2020-12-25 |
KR20210005910A (ko) | 2021-01-15 |
PH12020551772A1 (en) | 2021-07-12 |
JP7360132B2 (ja) | 2023-10-12 |
US20210147448A1 (en) | 2021-05-20 |
JPWO2019208797A1 (ja) | 2021-05-27 |
EA202092579A1 (ru) | 2021-04-01 |
BR112020021631A2 (pt) | 2021-01-26 |
EP3786168A1 (en) | 2021-03-03 |
EP3786168A4 (en) | 2022-03-23 |
WO2019208797A1 (ja) | 2019-10-31 |
BR112020021631A8 (pt) | 2023-02-28 |
US11702431B2 (en) | 2023-07-18 |
US11066425B1 (en) | 2021-07-20 |
CA3098433A1 (en) | 2019-10-31 |
TWI829686B (zh) | 2024-01-21 |
AU2019259818B2 (en) | 2023-06-01 |
AU2019259818A1 (en) | 2020-11-26 |
US20230287009A1 (en) | 2023-09-14 |
SG11202010661SA (en) | 2020-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
AU2017268006A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
GEP20237522B (en) | Antibacterial compounds | |
PH12020551772A1 (en) | Oxo-substituted compound | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021012105A (es) | Compuestos de pirrol. | |
WO2023129958A3 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
MX2019006768A (es) | Peptidos antimicrobianos. | |
MX2022004912A (es) | Novedoso compuesto de anillo condensado sustituido. | |
PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX2019004187A (es) | Inhibidores de bromodominios. | |
ZA202203106B (en) | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections | |
ZA202203108B (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections | |
ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
MX2021001349A (es) | Un nuevo tratamiento medico para la inflamacion patologica. | |
MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. |